SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Pictured: Healthcare worker examining a hand X-ray
Drug Development
Bone Therapeutics is Breaking New Ground in Bone Remodeling
Complicated bone fractures take a long while to heal. Bone Therapeutics S.A. is developing a cell therapy product that speeds bone regeneration and just may solve that problem.
May 8, 2022
 · 
4 min read
 · 
Gail Dutton
CinCor CFO Terry Coelho, Courtesy CinCor
Business
CinCor’s Terry Coelho is Building Bridges Between Finance & Business Units
For Terry Coelho, being CFO is about becoming a trusted strategic partner across the business. It’s about building bridges.
May 5, 2022
 · 
4 min read
 · 
Gail Dutton
Awakn Co-founder and CEO Anthony Tennyson/Courtesy
Business
Awakn’s Anthony Tennyson on Providing Hope for Those Suffering from Addiction
Awakn researches and develops drug-assisted psychotherapy treatments, focusing on psychedelic drugs to treat addiction.
May 4, 2022
 · 
6 min read
 · 
Gail Dutton
Drug Development
Context Therapeutics is Targeting Progesterone to Outsmart Tumors in Women’s Cancers
Context Therapeutics’ lead candidate ONA-XR prevents interaction between progesterone and its receptor, downregulates cancer stem cell mobilization and blocks immune evasion.
May 4, 2022
 · 
5 min read
 · 
Gail Dutton
Humacyte Founder, President and CEO Laura Niklason
Drug Development
Humacyte’s Engineered Blood Vessels in Final Push Toward BLA
Humacyte’s engineered blood vessels, human acellular vessels, are in a position to take tissue regeneration from a laboratory possibility to a commercial reality.
May 3, 2022
 · 
5 min read
 · 
Gail Dutton
An illustration of bond formation /courtesy of Ver
Drug Development
Verseon’s Atomic-Level Drug Design is Changing the Paradigm of Drug Discovery
What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules. The company has 14 small molecule drugs in development.
May 2, 2022
 · 
5 min read
 · 
Gail Dutton
BryoLogyx CEO Tom Loarie, co-founder_BryoLogyx
Business
BryoLogyx Increases Antigen Visibility for an Enhanced I-O Impact
Bryostatin-1 increases antigen expression on the surface of cancer cells, enabling them to be seen and killed by IO agents.
April 27, 2022
 · 
4 min read
 · 
Gail Dutton
Business
The 9 Things Wildly Successful Biotechs Have in Common
Successful biotech companies have a certain way of thinking that propels everyone working there beyond day-to-day concerns and enables them to do great things. BioSpace highlights nine commonalities.
April 26, 2022
 · 
5 min read
 · 
Gail Dutton
Alex Tai/SOPA Images/LightRocket via Getty, Lance
Biotechs Turn to M&A as Liquidity Surges and Market Caps Falter
Biotech companies are facing sharp declines in stock prices, while venture capital and private equity are experiencing increases. BDO Life Sciences’ Lance Minor sat down BioSpace’s Gail Dutton.
April 24, 2022
 · 
5 min read
 · 
Gail Dutton
Sarah Silbiger/Getty Images
Business
The COVID-19 Pandemic will End, with Implications for Biopharma
The COVID-19 pandemic will end one day and, when it does, some biopharma companies will need to revert to a more normal way of working with others.
April 21, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
Alzamend Intends to Make Lithium Safer for Alzheimer’s, Bipolar Disorder
The possible addition of a new lithium-based drug to the list of available therapeutics is important because many physicians are reluctant to prescribe lithium.
April 19, 2022
 · 
4 min read
 · 
Gail Dutton
Bright Path Laboratories CEO Tony Quiñones/Courtes
Drug Development
Life Sciences Supply Chain Disruptions Likely to Persist through 2022
To cope, life sciences companies are undertaking a supply chain risk assessment, conducting make-or-buy assessments, investing in supply chain technology and identifying backup suppliers.
April 18, 2022
 · 
4 min read
 · 
Gail Dutton
Marc Voigt_courtesy of Immutep S.A./Dr. Omid Hamid
Drug Development
AACR: Advances in Immune System Stimulation and Cell Transplants Favor Oncology
BioSpace looked at some of the efforts to improve the host system’s immune response, as well as others to improve allogeneic or autologous cell transplants.
April 15, 2022
 · 
6 min read
 · 
Gail Dutton
Convergent Therapeutics CEO Philip Kantoff/Courtes
Business
AACR: Philip Kantoff Discusses Convergent’s Unique Path to Treating Prostate Cancer
Philip Kantoff, CEO of Convergent Therapeutics, spoke to BioSpace before the American Association for Cancer Research Annual Meeting on April 8-13 about CONV01-α.
April 14, 2022
 · 
6 min read
 · 
Gail Dutton
EXUMA VP Oncology, R&D Sid Kerkar, M.D/Courtesy EX
Drug Development
EXUMA’s CAR-TaNK Cells Could Eliminate Need for Preparative Chemotherapy
EXUMA Biotech is developing a new modality to produce CAR cells in a single day, with potentially lower toxicity and higher efficacy without the need for preparative chemotherapies.
April 11, 2022
 · 
3 min read
 · 
Gail Dutton
Load More